Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2005 3
2006 3
2007 3
2008 2
2010 4
2011 3
2012 3
2013 4
2014 7
2015 6
2016 3
2017 7
2018 5
2019 17
2020 21
2021 26
2022 22
2023 18
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Results by year

Filters applied: . Clear all
Page 1
Rituximab treatment of myasthenia gravis: A systematic review.
Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Tandan R, et al. Muscle Nerve. 2017 Aug;56(2):185-196. doi: 10.1002/mus.25597. Epub 2017 Mar 21. Muscle Nerve. 2017. PMID: 28164324 Review.
Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab in 169 myasthenia gravis (MG) patients from case reports and series. Antibodies to the acetylcholine receptor (AChR) were present in 59% and mus …
Rituximab is a chimeric mouse/human anti-CD20 monoclonal immunoglobulin. We reviewed the efficacy and safety of rituximab in 169 myasthen …
Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis.
Saccà F, Pane C, Espinosa PE, Sormani MP, Signori A. Saccà F, et al. Eur J Neurol. 2023 Dec;30(12):3854-3867. doi: 10.1111/ene.15872. Epub 2023 May 30. Eur J Neurol. 2023. PMID: 37204031
BACKGROUND AND PURPOSE: Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. ...No significant difference emerged between complement inhibitors and anti-FcRn treatment (p = 0.16). The change in Quantitative Myasthe …
BACKGROUND AND PURPOSE: Therapy for myasthenia gravis (MG) is undergoing a profound change, with new treatments being tested. …
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Safa H, et al. J Immunother Cancer. 2019 Nov 21;7(1):319. doi: 10.1186/s40425-019-0774-y. J Immunother Cancer. 2019. PMID: 31753014 Free PMC article. Review.
BACKGROUND: Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). ...
BACKGROUND: Myasthenia gravis (MG) is a rare but life-threatening adverse event of immune checkpoint inhibitors (ICI). ...
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders.
Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, Crowley C, Boyman O. Kaegi C, et al. Front Immunol. 2019 Sep 6;10:1990. doi: 10.3389/fimmu.2019.01990. eCollection 2019. Front Immunol. 2019. PMID: 31555262 Free PMC article.
Conclusions: Rituximab is both safe and effective for the treatment of acquired angioedema with C1-inhibitor deficiency, ANCA-associated vasculitis, autoimmune hemolytic anemia, Behcet's disease, bullous pemphigoid, Castleman's disease, cryoglobulinemia, Goodpasture's disease, Ig …
Conclusions: Rituximab is both safe and effective for the treatment of acquired angioedema with C1-inhibitor deficiency, ANCA-associated vas …
Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis.
Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, Shohaimi S, Mohammadi M. Salari N, et al. J Transl Med. 2021 Dec 20;19(1):516. doi: 10.1186/s12967-021-03185-7. J Transl Med. 2021. PMID: 34930325 Free PMC article.
BACKGROUND: Myasthenia gravis is a neuromuscular autoimmune disorder characterized by weakness and disability in the voluntary muscles. There have been several preliminary studies on the epidemiology of myasthenia gravis in different parts of the world …
BACKGROUND: Myasthenia gravis is a neuromuscular autoimmune disorder characterized by weakness and disability in the voluntary …
Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Pathak R, et al. Oncologist. 2021 Dec;26(12):1052-1061. doi: 10.1002/onco.13931. Epub 2021 Aug 25. Oncologist. 2021. PMID: 34378270 Free PMC article.
In recent years, several cases of myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS) have been reported. However, given the rarity, the clinical features and outcomes of these cases remain poorly understood. ...IMPLICATIONS FOR PRACTICE: Cli …
In recent years, several cases of myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS) have been report …
Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis.
Morales-Ruiz V, Juárez-Vaquera VH, Rosetti-Sciutto M, Sánchez-Muñoz F, Adalid-Peralta L. Morales-Ruiz V, et al. Autoimmun Rev. 2022 Mar;21(3):103019. doi: 10.1016/j.autrev.2021.103019. Epub 2021 Dec 15. Autoimmun Rev. 2022. PMID: 34920107 Review.
OBJECTIVE: To compare the efficacy of IVIg administration with that of corticosteroids, plasmapheresis, and placebo in autoimmune neurological diseases like Guillain-Barre syndrome, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, optic neuritis …
OBJECTIVE: To compare the efficacy of IVIg administration with that of corticosteroids, plasmapheresis, and placebo in autoimmune neurologic …
Neurogenic Dysphagia: Systematic Review and Proposal of a Classification System.
Warnecke T, Labeit B, Schroeder J, Reckels A, Ahring S, Lapa S, Claus I, Muhle P, Suntrup-Krueger S, Dziewas R. Warnecke T, et al. Neurology. 2021 Feb 9;96(6):e876-e889. doi: 10.1212/WNL.0000000000011350. Epub 2020 Dec 14. Neurology. 2021. PMID: 33318164
Seven dysphagia phenotypes were identified: (1) "premature bolus spillage" and (2) "delayed swallowing reflex" occurred mainly in stroke, (3) "predominance of residue in the valleculae" was most common in Parkinson disease, (4) "predominance of residue in the piriform sinus" occu …
Seven dysphagia phenotypes were identified: (1) "premature bolus spillage" and (2) "delayed swallowing reflex" occurred mainly in stroke, (3 …
Respiratory muscle training in children and adults with neuromuscular disease.
Silva IS, Pedrosa R, Azevedo IG, Forbes AM, Fregonezi GA, Dourado Junior ME, Lima SR, Ferreira GM. Silva IS, et al. Cochrane Database Syst Rev. 2019 Sep 5;9(9):CD011711. doi: 10.1002/14651858.CD011711.pub2. Cochrane Database Syst Rev. 2019. PMID: 31487757 Free PMC article.
MAIN RESULTS: We included 11 studies involving 250 randomized participants with NMDs: three trials (N = 88) in people with amyotrophic lateral sclerosis (ALS; motor neuron disease), six trials (N = 112) in Duchenne muscular dystrophy (DMD), one trial (N = 23) in people with Becke …
MAIN RESULTS: We included 11 studies involving 250 randomized participants with NMDs: three trials (N = 88) in people with amyotrophic later …
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.
Garred P, Tenner AJ, Mollnes TE. Garred P, et al. Pharmacol Rev. 2021 Apr;73(2):792-827. doi: 10.1124/pharmrev.120.000072. Pharmacol Rev. 2021. PMID: 33687995 Free PMC article.
Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia gravis, and neuromyelitis optica spectrum disorders. Rare diseases, unfortunately, preclude robust clinical trials. ...
Those currently being efficiently treated include paroxysmal nocturnal hemoglobinuria, atypical hemolytic-uremic syndrome, myasthenia …
145 results